In episode #200 of Cardionerds: A Cardiology Podcast, special co-host Dr. Mark Belkin and the Journal of Cardiac Failure team discuss the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Editors Dr. Robert Mentz, Dr. Anu Lala, and FIT editors highlight patient-centered updates and practice-changing guidance for diagnosing and managing heart failure, including newer therapeutics like SGLT2 inhibitors, emphasizing holistic care and improved patient outcomes.

Key takeaways from the guidelines include the addition of SGLT2 inhibitors in the treatment for heart failure with reduced ejection fraction (HFrEF), and recommendations for mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF). Other important points are the continuation of HFrEF treatment for patients with improved left ventricular ejection fraction (LVEF), new treatments for amyloid heart disease, and the importance of diagnosing HF with LVEF >40% through increased filling pressures. The guidelines also stress primary prevention for those at risk, referrals to HF specialty teams for advanced cases, and tailored recommendations for patients with various comorbid conditions.

Reference: 200.2022 AHA/ACC/HFSA Guideline for The Management of Heart Failure – Hot Takes from The Journal of Cardiac Failure Family. Accessed June 5, 2024. https://www.cardionerds.com/200-2022-acc-aha-hfsa-guideline-for-the-management-of-heart-failure-hot-takes-from-the-journal-of-cardiac-failure-family/